Pulmonary fibrosis

Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research

Retrieved on: 
Wednesday, April 3, 2024
Cardiovascular disease, Patient, SAN, Biomarker, Bristol Myers Squibb, Protein, Proteomics, Science, Pulmonary fibrosis, Clinical trial, HCM, Heart, Hypertrophic cardiomyopathy, Translational medicine, Pharmaceutical industry

The SomaScan Platform is a high-throughput proteomics technology that presents a vast data landscape for researchers to explore by providing a comprehensive analysis of proteomic biomarkers.

Key Points: 
  • The SomaScan Platform is a high-throughput proteomics technology that presents a vast data landscape for researchers to explore by providing a comprehensive analysis of proteomic biomarkers.
  • These proteins enable a dynamic view into how patients respond to drugs, giving researchers insight into a drug’s success while minimizing invasive testing.
  • Bristol Myers Squibb has been an early adopter of the protein-based SomaScan Platform in immunology, cardiovascular disease and pulmonary fibrosis.
  • “Bristol Myers Squibb is a valued partner, and we are pleased to be collaborating on the development of these new tools that will accelerate insights into disease response,” says Michael Egholm, President and Chief Executive Officer of Standard BioTools™.

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Retrieved on: 
Wednesday, April 3, 2024
Research, Extracellular matrix, B cell, ECM, Regeneration, Idiopathic pulmonary fibrosis, AT2, Inflammation, Lung, SWAP, Respiratory Research, Macrophage, IPF, Pulmonary fibrosis, Fibrosis, Therapy, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, announced today publication of data in Respiratory Research highlighting the potential for Surrozen’s Wnt mimetic technologies to treat serious lung diseases like idiopathic pulmonary fibrosis (IPF) https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-0.... The results observed with systemic administration of Surrozen’s Wnt mimetic antibody in an acute bleomycin model of pulmonary fibrosis demonstrate a Wnt pathway mediated decrease in inflammation and fibrosis and improvement in lung function.

Key Points: 
  • The results observed with systemic administration of Surrozen’s Wnt mimetic antibody in an acute bleomycin model of pulmonary fibrosis demonstrate a Wnt pathway mediated decrease in inflammation and fibrosis and improvement in lung function.
  • Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by areas of myofibroblast accumulation and extracellular matrix (ECM) deposition, disruption of alveolar architecture, and restricted lung physiology.
  • In pulmonary fibrosis, multiple cell types may need to be targeted to provide a regenerative environment facilitating repair.
  • “This work published in Respiratory Research represents a breakthrough in understanding the role of the Wnt pathway in lung fibrosis and the potential for Wnt mimetics to reduce fibrosis and improve lung function.”

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Atopic dermatitis, Head, T helper cell, HNSCC, Patient, PTCL, Lung cancer, Ipilimumab, Asthma, CTCL, ALCL, Fungal infection, Pulmonary fibrosis, Lymphocyte, RCC, Clinical trial, CRS, Marketing, B-cell lymphoma, Research, PR, PTCL-NOS, Psoriasis, T-cell lymphoma, ASH, Webcast, Immunomodulation, Pembrolizumab, PRS, Exposition, Cancer, Nivolumab, Safety, Scleroderma, Food, NSCLC, Teva Pharmaceuticals, Modified, Lymphoma, Knowledge, Allergy, Immunodeficiency, Time management, Peripheral, Poster, FDA, ITK, Conference call, Kidney cancer, T helper 17 cell, Society, Preprint, BioRxiv, Autoimmunity, Physician, Total, Pharmaceutical industry

BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • We have several exciting opportunities in immunology, including plans for a randomized, placebo controlled clinical trial of soquelitinib in atopic dermatitis.
  • Mr. Arcara previously served as senior vice president, head global marketing & portfolio and strategy for the innovative medicines and biosimilars business at Teva Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2023 financial results.

Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals

Retrieved on: 
Tuesday, April 2, 2024
Professional Services, Philanthropy, Pharmaceutical, Sustainability, DEI (Diversity, Equity and Inclusion), Environment, Clinical Trials, Biotechnology, Human Resources, Climate Change, Other Philanthropy, Health, Environmental, Social and Governance (ESG), Electricity, BMY, Multiple myeloma, Science, Health equity, ESG, Patient, VPPA, Ethics, Pulmonary fibrosis, Research, Climate, Female, Artificial intelligence, BMS, Bristol Myers Squibb, Doctor of Philosophy, Clinical trial, Task force, TCFD, Lupus, Patient safety, Workforce, Chairperson, Improvement, Multimedia, Privacy, Targets, Developing country, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company’s meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today published its 2023 Environmental, Social, and Governance (ESG) Report detailing the company’s meaningful progress, evolved strategy, and aspirational goals toward its ESG efforts.
  • The company’s ESG strategy is embedded in its mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
  • View the full release here: https://www.businesswire.com/news/home/20240402638203/en/
    “For more than 130 years, BMS has enabled positive change for our patients around the world.
  • Incorporated new ESG metrics into the executive compensation program, measuring achievement against environmental and social goals and better aligning executive bonuses with company strategy.

Partner Therapeutics' Leukine® (sargramostim) Receives Approval in Japan to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Retrieved on: 
Wednesday, April 3, 2024
Monocyte, GM, Serum, Disease, Partnership, Patient, GM-CSF, DNA, PTX, Doctor of Philosophy, Respiratory failure, Pleasure, Trade name, Granulocyte-macrophage colony-stimulating factor, Pulmonary fibrosis, APAP, Therapy, Niigata University, Pulmonary alveolar proteinosis, Division, Partner, PMDA, PAGE, CEA, WLL, Hospital

LEXINGTON, Mass., April 3, 2024 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) announced that its partner Nobelpharma received approval from the Japanese Pharmaceuticals and Medical Device Agency (PMDA) for the inhaled use of Leukine (sargramostim), branded in Japan as Sargmalin, to treat aPAP. PTx licensed rights for certain indications in Japan to Nobelpharma in 2022. Leukine is a glycosylated recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in yeast. Leukine is not approved outside Japan for aPAP or as an inhalation therapy. Partner Therapeutics will manufacture Sargmalin for Nobelpharma at its manufacturing facility in Lynnwood, WA.

Key Points: 
  • Leukine is not approved outside Japan for aPAP or as an inhalation therapy.
  • Partner Therapeutics will manufacture Sargmalin for Nobelpharma at its manufacturing facility in Lynnwood, WA.
  • Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients.
  • Autoimmune pulmonary alveolar proteinosis.

Early Pulmonary Fibrosis Detection Holds the Key to Better Health Outcomes for Canadians Living with COVID-19 and Rheumatoid Arthritis

Retrieved on: 
Wednesday, February 28, 2024
Rare disease, Oxygen, Connective tissue disease, Research, Scleroderma, Physician, St. Joseph's Health Centre, Lupus, Crackle, Myositis, Pulmonary fibrosis, Life, CPFF, COVID-19, Signs, Rheumatoid arthritis, COVID, Patient, Disease, Diagnosis, Connective tissue, Interview, Face, Pharmaceutical industry

Canadians who have had COVID-19, and other chronic diseases, are experiencing Pulmonary Fibrosis (PF) at significantly higher rates than others, seemingly providing a causal link that researchers are investigating.

Key Points: 
  • Research is shedding light on the growing rate of pulmonary fibrosis (PF) being found in people suffering from long-term COVID-19.
  • One study, Post COVID-19 pulmonary fibrosis; a meta-analysis study , found that almost 45% (44.9%) of study participants began suffering from PF after contracting COVID-19.
  • Canadians suffering from long COVID are encouraged to watch for the early signs of pulmonary fibrosis, a disease that is growing in this population.
  • Dr. Janet Pope's webinar includes explanations for both physicians and thousands of people living with connective tissue diseases of what pulmonary fibrosis symptoms to watch for.

Broadway Belts for PFF! Extravaganza Raises Voices and Funds for Pulmonary Fibrosis

Retrieved on: 
Thursday, March 7, 2024
Come, Infant, PFF, Grammy Awards, City, Future, Ralph Howard, Pulmonary fibrosis, Divinity, Family, The King, Sony Hall, Cagney, Miss Saigon, Research, Confession, Nightclub

CHICAGO, March 7, 2024 /PRNewswire/ -- Prepare for a night of pure Broadway magic as the stars align for the Pulmonary Fibrosis Foundation's (PFF) 14th annual Broadway Belts for PFF!

Key Points: 
  • CHICAGO, March 7, 2024 /PRNewswire/ -- Prepare for a night of pure Broadway magic as the stars align for the Pulmonary Fibrosis Foundation's (PFF) 14th annual Broadway Belts for PFF!
  • "The Broadway community stands together in solidarity with those affected by pulmonary fibrosis," said Julie Halston.
  • Since its inception, Broadway Belts for PFF!, has raised over $3 million for PF research and support programs.
  • To purchase tickets and for more information about Broadway Belts for PFF!, visit broadwaybeltsforpff.org .

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

Retrieved on: 
Monday, February 12, 2024
Atopic dermatitis, Immunodeficiency, Psoriasis, Infection, SQL, ITK, Scleroderma, Preprint, Asthma, T helper cell, Pulmonary fibrosis, T helper 17 cell, Venn, Lymphocyte, Cytokine, Rheumatoid arthritis, Immunosuppression, Dermatitis, Publication, Lymphoma, Research, Immunomodulation, Vaccine

BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.

Key Points: 
  • BURLINGAME, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that preclinical data for soquelitinib, the Company’s lead ITK inhibitor program, was presented in a poster session at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases, which took place February 8-11, 2024.
  • These preclinical product candidates exhibit specific biologic properties that are anticipated to enable more precise inhibition of Th1, Th2 and/or Th17 cell function.
  • Atopic dermatitis (also called eczema) and asthma are thought to be mediated primarily by Th2 lymphocytes.
  • The soquelitinib preclinical data and information on the Company’s next-generation ITK inhibitor candidates was presented by Rahul Pawar, Ph.D., Senior Scientist at Corvus, in poster session #2 (poster #2008) at the Keystone Symposia.

AnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic Sclerosis

Retrieved on: 
Monday, February 5, 2024
Inflammation, Systemic scleroderma, Biomarker, Patient, Diagnosis, FDA, EMA, Marketing, Scleroderma, Interstitial lung disease, Skin, Pulmonary fibrosis, Disability, Disease, Fibrosis, European Medicines Agency, Death, ODD, Autoimmune disease, ILD, Organ dysfunction, Pharmaceutical industry

AM1476 offers a unique dual-action approach to treat both skin and lung manifestations of systemic sclerosis.

Key Points: 
  • AM1476 offers a unique dual-action approach to treat both skin and lung manifestations of systemic sclerosis.
  • Systemic sclerosis is a chronic, progressive, autoimmune disease characterized by inflammation and fibrosis, i.e.
  • AnaMar's Chief Executive Officer, Dr. Ulf Ljungberg, said: “We are delighted with the FDA’s and EMA’s decisions to grant orphan drug designation to AM1476 for SSc.
  • Orphan drug designation provides certain benefits, including the potential for extensive marketing exclusivity following regulatory approval, reduction in regulatory fees and, in the case of EU, a centralized approval process.

MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19

Retrieved on: 
Wednesday, January 31, 2024
Long COVID, ICU, COVID-19, Mortality, Standard of care, HERA, Clinical trial, Pulmonary fibrosis, Patient, Safety, Virus, SOC, CT-05, Disease, Infection, Phases of clinical research, WHO, Pharmaceutical industry

A total of 131 COVID-19 patients were treated with Standard of Care (SoC) plus MetrioPharm’s lead compound MP1032 or with placebo.

Key Points: 
  • A total of 131 COVID-19 patients were treated with Standard of Care (SoC) plus MetrioPharm’s lead compound MP1032 or with placebo.
  • Patients treated with MP1032 (n=86) exhibited a lower mortality compared to those receiving placebo + SoC (n=45).
  • Moreover, the efficacy of MP1032 was enhanced when used in combination with anti-viral agents, including, but not limited to, remdesivir.
  • These protocols had been defined with much larger studies in mind,” said MetrioPharm CSO and co-founder Dr. Wolfgang Brysch.